PFE - ESSA Pharma: Promising Novel Therapy For Treatment Of Prostate Cancer
ESSA Pharma Inc. (EPIX) [TSX-V: EPI] is a Canadian/U.S. pre-clinical stage pharmaceutical company focused on the development of novel treatments of prostate cancer in patients whose disease is progressing despite treatment with current therapies, including abiraterone and enzalutamide.
On September 27th, I had a chance to meet with ESSA's CEO Dr. David Parkinson, MD, EVP & COO Peter Virsik, and CFO David Wood.
I was impressed with ESSA's story.
In the article below, the slides referenced are all taken from ESSA's presentation at Ladenburg Thalmann on September 24, 2019. The slides and webcast are currently